RxDoctor Payments Data

Jeffrey Ellison, MD

Gastroenterology · Fayetteville, ARNPI 1407040488

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 45.2% of the total.

$5,702in general payments, 2019–2025

Across 345 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$412
  • Johnson & Johnson$332
  • Pfizer$317
  • Braintree Laboratories, Inc.$256
  • Gilead$244
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,44696%
  • Education$641%
  • Gifts$1913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,702 in reported general payments places this provider in the 65th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$187,116
Medicare patients
345
Services billed
5,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin19$55,791
CreonLipase/Protease/Amylase11$17,165
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates177$11,440
Ursodiol38$6,591
SutabSod Sulf/Pot Chloride/Mag Sulf34$5,485
Dexlansoprazole DrDexlansoprazole12$4,433
Budesonide DrBudesonide23$4,165
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$4,138
Sucralfate105$4,079
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C20$2,781
Colestipol Hcl90$2,531
Pantoprazole Sodium320$2,413
Azathioprine29$1,273
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$591
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl32$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$412$58,57239 claims
AbbVieCreon$2,577$17,16511 claims
Braintree Laboratories, Inc.Sutab$256$5,48534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →